A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee
NCT05931367 on ClinicalTrials.gov · last registry update 2026-01-21
Finished 14 November 2025, after enrolling 445 people. Primary outcome, as filed: Change from Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score. retatrutide is not approved in the US for anything yet, so this is a drug in development rather than an established treatment being extended.
- Status
- COMPLETED
- Phase
- P3
- Drug
- retatrutide
- Sponsor
- Eli Lilly and Company
- Sponsor type
- Industry
- Enrollment
- 445
- Started
- 2023-08-01
- Primary completion
- 2025-11-14 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Change from Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score
Conditions studied
Obesity · Overweight · Osteo Arthritis Knee
Every field above is taken directly from the registry record. See all detected changes across the class, or the retatrutide page for this molecule’s full trial and approval history.